Literature DB >> 27449398

Hesperetin and Naringenin sensitize HER2 positive cancer cells to death by serving as HER2 Tyrosine Kinase inhibitors.

Bhavya Balan Chandrika1, Mathew Steephan2, T R Santhosh Kumar3, A Sabu4, M Haridas5.   

Abstract

AIM: Aberrant human epidermal growth factor receptor-2 (HER2) expression and constitutive mutant activation of its tyrosine kinase domain account for tumor aggression and therapy resistance in many types of cancers with major share in breast cancer cases. HER2 specific treatment modalities still face challenges owing to the side effects and acquired resistance of available therapeutics. Recently, the anti-proliferative and pro-apoptotic potential of phytochemicals, especially of flavonoids have become increasingly appreciated as powerful chemo preventive agents. Consequently, the major goal of our study is to identify flavonoids capable of inhibiting HER2 Tyrosine Kinase (HER2-TK) activity and validate their anti-tumor activity against HER2 positive tumors. MAIN
METHODS: Molecular docking studies for identifying flavonoids binding at HER2 kinase domain, ADP-Glo™ Kinase Assay for determining kinase activity, MTT assay to measure growth inhibition, various apoptotic assays and cell cycle analysis by FACS were performed. KEY
FINDINGS: Among the flavonoids screened, Naringenin (NG) and Hesperetin (HP) possessed high glide scores from molecular docking studies of enzyme-inhibitor mode. The interaction analysis revealed their ability to establish stable and strong interaction at the ATP binding site of HER2-TK. These compounds also inhibited in vitro HER2-TK activity suggesting their role as HER2 inhibitors. The study also unraveled the anti-proliferative, pro-apoptotic and anti-cancerous activity of these flavonoids against HER2 positive breast cancer cell line. SIGNIFICANCE: The study identified two citrus fruit flavonoids, NG and HP as HER2-TK inhibitors and this is the first report on their potential to target preferentially and sensitize HER2 positive cancer cells to cell death.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-cancer agents; Flavonoids; HER2 positive; HER2-TK; HER2-Tyrosine Kinase inhibitors; Hesperetin; Naringenin

Mesh:

Substances:

Year:  2016        PMID: 27449398     DOI: 10.1016/j.lfs.2016.07.007

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  13 in total

Review 1.  Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs.

Authors:  Nan Jiang; Jing-Jing Lin; Jun Wang; Bei-Ning Zhang; Ao Li; Zheng-Yang Chen; Song Guo; Bin-Bin Li; Yu-Zhong Duan; Ru-Yi Yan; Hong-Feng Yan; Xiao-Yan Fu; Jin-Lian Zhou; He-Ming Yang; Yan Cui
Journal:  Exp Ther Med       Date:  2018-07-17       Impact factor: 2.447

Review 2.  Flavonoids: structure-function and mechanisms of action and opportunities for drug development.

Authors:  Stephen Safe; Arul Jayaraman; Robert S Chapkin; Marcell Howard; Kumaravel Mohankumar; Rupesh Shrestha
Journal:  Toxicol Res       Date:  2021-01-20

3.  Citrus aurantium Naringenin Prevents Osteosarcoma Progression and Recurrence in the Patients Who Underwent Osteosarcoma Surgery by Improving Antioxidant Capability.

Authors:  Lirong Zhang; Xiaohua Xu; Tiechao Jiang; Kunzhe Wu; Chuanbo Ding; Zhen Liu; Xuanhe Zhang; Tianhua Yu; Changlong Song
Journal:  Oxid Med Cell Longev       Date:  2018-02-07       Impact factor: 6.543

4.  Development and Optimization of a High Sensitivity LC-MS/MS Method for the Determination of Hesperidin and Naringenin in Rat Plasma: Pharmacokinetic Approach.

Authors:  Jesús Alfredo Araujo-León; Rolffy Ortiz-Andrade; Rivelino Armando Vera-Sánchez; Julio Enrique Oney-Montalvo; Tania Isolina Coral-Martínez; Zulema Cantillo-Ciau
Journal:  Molecules       Date:  2020-09-16       Impact factor: 4.411

5.  Cytotoxic and Antimetastatic Activity of Hesperetin and Doxorubicin Combination Toward Her2 Expressing Breast Cancer Cells.

Authors:  Ika Putri Nurhayati; Annisa Khumaira; Gagas Pradani Nur Ilmawati; Edy Meiyanto; Adam Hermawan
Journal:  Asian Pac J Cancer Prev       Date:  2020-05-01

6.  Identification of potential therapeutic target of naringenin in breast cancer stem cells inhibition by bioinformatics and in vitro studies.

Authors:  Adam Hermawan; Muthi Ikawati; Riris Istighfari Jenie; Annisa Khumaira; Herwandhani Putri; Ika Putri Nurhayati; Sonia Meta Angraini; Haruma Anggraini Muflikhasari
Journal:  Saudi Pharm J       Date:  2020-12-15       Impact factor: 4.330

7.  The Cytotoxic and Antimigratory Activity of Brazilin-Doxorubicin on MCF-7/HER2 Cells.

Authors:  Riris Istighfari Jenie; Sri Handayani; Ratna Asmah Susidarti; Linar Zalinar Udin; Edy Meiyanto
Journal:  Adv Pharm Bull       Date:  2018-08-29

8.  Naringenin exerts anticancer effects by inducing tumor cell death and inhibiting angiogenesis in malignant melanoma.

Authors:  Jawun Choi; Dae-Hyo Lee; Hyuk Jang; Sang-Youel Park; Jae-Won Seol
Journal:  Int J Med Sci       Date:  2020-10-18       Impact factor: 3.738

Review 9.  Stable Isotope Tracing Metabolomics to Investigate the Metabolic Activity of Bioactive Compounds for Cancer Prevention and Treatment.

Authors:  Feroza K Choudhury; G Lavender Hackman; Alessia Lodi; Stefano Tiziani
Journal:  Cancers (Basel)       Date:  2020-08-03       Impact factor: 6.639

Review 10.  Phytochemical and Ethnopharmacological Perspectives of Ehretia laevis.

Authors:  Pooja Sharma; Richa Shri; Fidele Ntie-Kang; Suresh Kumar
Journal:  Molecules       Date:  2021-06-08       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.